Abstract: The present disclosure relates to novel compounds that can be used as anti-cancer agents in the prostate cancer therapy. In particular, the invention relates to N-acyl derivatives of 2,3-dihydro-1H-pyrrolo[2,3-b]quinolines having the structural Formula (I), stereoisomers, tautomers, racemics, prodrugs, metabolites thereof, or pharmaceutically acceptable salt and/or solvate thereof. The meaning of R1 is independently selected from H; C1-C6 Alkyl, cyclo-Alkyl or iso-Alkyl substituents; R2 is selected from C1-C6 Alkyl, cyclo-Alkyl or iso-Alkyl; substituted or non-substituted, fused or non-fused to substituted or non-substituted aromatic ring, aryl or heteroaryl groups. The invention also relates to methods for preparing said compounds, and to pharmaceutical compositions comprising said compounds.

Abstract: The present disclosure relates to novel compounds that can be used as anti-cancer agents in the prostate cancer therapy. In particular, the invention relates N-substituted derivatives of 4-(hetero)aryl-1,2,5-oxadiazol-3-yl amines having the structural Formula (I) and (II), stereoisomers, tautomers, racemics, prodrugs, metabolites thereof, or pharmaceutically acceptable salt and/or solvate thereof. Meaning of R1 and R2 in the Formula (I) and (II) are defined in claim 1. The invention also relates to methods for preparing said compounds, and to pharmaceutical compositions comprising said compounds.

Abstract: The present invention concerns cyclopentadienylphosphazene complexes (CpPN complexes) of the metals of the third and fourth group and of the lanthanoids with the exception of lutetium. The complexes according to the present invention are isolobal and isoelectronic to [(CpSiN)TiR2] complexes. Exactly one CpPN unit is present in the complexes according to the present invention. In all complexes according to the present invention, the cyclopentadienyl unit of CpPN represents a monodentate, anionic ligand of the metal atom. Furthermore, the metal atom is bound to further anionic ligands. In a preferred embodiment, both the cyclopentadienyl unit and the nitrogen atom are bound within CpPN to the metal atom, so that CpPN then represents a bidentate ligand. Complexes according to the present invention, in which CpN represents a bidentate ligand, are CpPN-constrained geometry complexes (CpPN-CGC). Furthermore, methods are provided for the in situ production of the complexes according to the present invention.

Abstract: The present invention relates to catalyst system containing at least one imidochrome compound and at least one activation compound. This invention also relates to imidochrome compounds, to a method for olefin polymerization and to methods for producing said imidochrome compounds.

Abstract: The present invention relates to catalyst system containing at least one imidochrome compound and at least one activation compound. This invention also relates to imidochrome compounds, to a method for olefin polymerization and to methods for producing said imidochrome compounds.

Abstract: The present invention relates to catalyst system containing at least one imidochrome compound and at least one activation compound. This invention also relates to imidochrome compounds, to a method for olefin polymerization and to methods for producing said imidochrome compounds.